Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

Sophie Wildsmith1, Weimin Li2, Song Wu3, Ross Stewart1, Nassim Morsli4, Rajiv Raja5, Qu Zhang6, Jiabu Ye2, Philip He2, Jagdish Shetty2, Alejandro Yovine1, Nicholas Holoweczyk2, Katia Rea1, Jill Walker1, Magdalena Wrona3, Melissa de los Reyes2, Craig Barker1, Jessica Whiteley1, Robert Haddad4, Lisa Licitra5, Robert Ferris6, Jérôme Fayette7, Dan P. Zandberg6, Lillian L. Siu8, and Ricard Mesía9

Purpose: Biomarkers that predict response to immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) are needed. This retrospective study assessed tumor mutational burden (TMB) and outcomes in the phase II HAWK and CONDOR and phase III EAGLE studies of durvalumab with or without tremelimumab in platinum-resistant R/M HNSCC.

Patients and Methods: Tumor samples from HAWK/CONDOR (N = 153) and blood samples from EAGLE (N = 247) were analyzed for TMB. Associations with survival were evaluated for tissue TMB (tTMB) at cutoffs from 10 to 20 mutations/megabase (mut/Mb) and for blood plasma TMB (bTMB) at cutoffs from 8 to 24 mut/Mb.

Results: In HAWK/CONDOR, overall survival (OS) with durvalumab and tremelimumab was longer for high versus low tTMB: statistically significant differences were observed with durvalumab plus tremelimumab at tTMB ≥ 10 mut/Mb [HR, 0.52 (95% confidence interval, CI, 0.28–0.98)] and tTMB ≥ 12 mut/Mb [HR, 0.46 (95% CI, 0.24–0.86)]. In EAGLE, a significant OS benefit versus chemotherapy was observed with durvalumab and durvalumab plus tremelimumab at bTMB≥16 mut/Mb [HR, 0.39 (95% CI, 0.20–0.76) and 0.38 (95% CI, 0.19–0.78), respectively] but not bTMB < 16 mut/Mb [HR, 0.92 (0.61–1.37) and 0.92 (95% CI, 0.62–1.36), respectively]. A significant progression-free survival benefit was also observed in the ICI arms versus chemotherapy at bTMB ≥ 16 mut/Mb.

Conclusions: Findings support TMB as a biomarker for predicting survival in patients with platinum-resistant R/M HNSCC treated with ICIs. The analysis of EAGLE demonstrated that bTMB was predictive of survival with ICI treatment versus chemotherapy in a large, randomized controlled study population.

Introduction

Patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) have a poor prognosis (1, 2). Immune checkpoint inhibitors (ICI) targeting CTLA-4 (CTLA-4), programmed cell death-1 (PD-1), or programmed cell death-ligand 1 (PD-L1) have been evaluated for second-line treatment of R/M HNSCC (3–5). The anti-PD-1 antibodies nivolumab and pembrolizumab demonstrated significantly improved overall survival (OS) versus standard of care (SoC: methotrexate, docetaxel, or cetuximab) in phase III studies (3, 4). In CheckMate 141, high PD-L1 expression was associated with higher objective response rates but was not significantly associated with longer OS for nivolumab versus single-agent SoC (3). In KEYNOTE-040, a greater OS benefit for pembrolizumab versus SoC was observed in the PD-L1–high subgroup than in the PD-L1–low subgroup (4). In the phase III EAGLE study, durvalumab (anti-PD-L1) with or without tremelimumab (anti-CTLA-4) demonstrated antitumor activity, but neither treatment regimen showed a significant OS benefit compared with investigator’s choice of SoC chemotherapy (5). While median OS for durvalumab was longer in patients with tumor cell (TC) PD-L1 expression ≥25% versus TC < 25% (9.8 vs. 7.6 months), OS in a small population of patients with TC < 1% was longer for durvalumab versus SoC (5).

On the basis of the results of the CheckMate 141 study, nivolumab monotherapy is approved by the FDA and European Medicines Agency (EMA) for the second-line treatment of R/M HNSCC (6, 7). Pembrolizumab in combination with platinum and 5-fluorouracil chemotherapy is approved by the FDA for the first-line treatment of R/M HNSCC. Pembrolizumab plus platinum and 5-fluorouracil chemotherapy is approved by the EMA, and pembrolizumab monotherapy is approved by the FDA and EMA, for first-line treatment of patients with R/M HNSCC whose tumors express PD-L1 with a combined positive score of ≥1 (8, 9). Pembrolizumab monotherapy is also approved by the FDA for the second-line treatment of R/M HNSCC and, based on the results of the KEYNOTE-040 study, by the...
Tumor Mutational Burden and Survival in Head and Neck Cancer

**Translational Relevance**

There is an ongoing need for improved strategies to select patients for treatment with immune checkpoint inhibitors (ICI) in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC). This study analyzed data from three studies of durvalumab (a PD-L1 inhibitor) with or without tremelimumab (a CTLA-4 inhibitor) to evaluate tumor mutational burden (TMB) as a predictive biomarker for ICI treatment outcomes in R/M HNSCC. In the phase II HAWK and CONDOR studies, patients with TMB-high tumors, determined at cutoffs of TMB ≥ 10 mutations (mut)/megabase (Mb) or TMB ≥ 12 mut/Mb, had longer overall survival (OS) than patients with TMB-low tumors. In the phase III EAGLE study, significant OS and progression-free survival benefit with durvalumab or durvalumab plus tremelimumab versus chemotherapy was observed in patients with high blood plasma TMB (tTMB), determined at a cutoff of TMB ≥ 16 mut/Mb, but not in patients with low bTMB. These findings demonstrate that TMB, including bTMB that can be measured noninvasively, is predictive of efficacy outcomes with ICIs and thus could be used to select patients with R/M HNSCC most likely to benefit from treatment with ICIs.

**Patients and Methods**

**Patients**

Patients with evaluable samples for biomarker analysis from the HAWK, CONDOR, and EAGLE trials were included. Patients were adults (ages ≥18 years) with histologically confirmed R/M HNSCC of the oral cavity, oropharynx, larynx, or hypopharynx, and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients had tumor progression or recurrence during or after treatment with one systemic platinum-based regimen for R/M disease (HAWK/CONDOR/EAGLE) or progression within 6 months of the last dose of platinum given as part of multimodality therapy with curative intent (EAGLE).

HAWK, CONDOR, and EAGLE were performed in accordance with ethical principles that have their origin in the Declaration of Helsinki and are consistent with International Conference on Harmonisation/Good Clinical Practice guidelines, applicable regulatory requirements, and the AstraZeneca policy on Bioethics and Human Biological Samples. Each patient provided informed written consent before conducting any procedure specifically for HAWK, CONDOR, or EAGLE. All patients gave informed consent for the use of biological samples for biomarker analysis. Investigations were performed after approval by an Institutional Review Board or Ethics Committee at participating sites.

**Study designs and treatment**

HAWK was an international, multicenter, single-arm phase II study of durvalumab involving patients with platinum-refractory R/M HNSCC tumors with high PD-L1 expression (24). CONDOR was an international, multicenter, open-label, phase II study in which patients with PD-L1–low tumors were randomized 1:1:2 to receive durvalumab, durvalumab plus tremelimumab, or SoC. randomization was stratified according to human papillomavirus (HPV) status and smoking status (25). EAGLE was an international, multicenter, open-label, phase III trial in which patients (regardless of PD-L1 expression) were randomized 1:1:1 to receive durvalumab, durvalumab plus tremelimumab, or SoC. randomization was stratified according to PD-L1 expression, tumor location, HPV status, and smoking status (5).

**TMB analysis datasets**

TMB analysis was performed on tumor samples collected from the patients enrolled in the HAWK and CONDOR studies. Baseline samples were up to 3 years old. Data from the durvalumab monotherapy arm of CONDOR were combined with data from HAWK for this analysis. The durvalumab plus tremelimumab arm from CONDOR was evaluated separately. Analysis of TMB was performed on plasma samples collected at baseline from patients in the EAGLE study until protocol version 6.

**Evaluation of TMB and determination of cutoffs**

For tTMB, whole-exome sequencing (WES) with 100 million reads at 200X coverage was conducted on archival formalin-fixed, paraffin-embedded tumor and patient-matched blood samples using the HiSeq 4000 System (Illumina Inc.) for 2 × 100 paired end reads. Somatic alterations were identified using VarDict (26). Only single-nucleotide variants and small insertions and deletions (<20 bp) with an allele frequency between 5% and 80% and were retained. tTMB was analyzed to evaluate the predictive value of blood plasma TMB (bTMB), PD-L1, and NLR for outcomes with treatment with ICIs compared with SoC.
Wildsmith et al.
calculated as the number of nonsynonymous somatic alterations
divided by the WES panel size of 30 Mb.
For bTMB, circulating tumor DNA was evaluated in blood plasma
samples using the Guardant Health OMNI platform, a targeted next-
generation sequencing platform using a 500-gene panel with a 2-Mb
DNA footprint (1 Mb coding regions only). The Guardant Health
bTMB algorithm incorporated somatic single-nucleotide variants and
insertions/deletions and accounted for low tumor shedding or low cell-
free DNA input.
A series of tTMB cutoff values ranging from 10 to 20 mut/Mb were
assessed to determine the optimal HR for OS between tTMB-high and
tTMB-low for each treatment group. A series of bTMB cutoff values
ranging from 8 to 24 mut/Mb were assessed to determine the optimal
HR for survival endpoints with durvalumab and durvalumab plus
tremelimumab compared with SoC. Two-fold cross-validation anal-
yses were performed, and cutoffs were selected using a minimum
P-value approach based on a Cox proportional hazards model. The
most frequently selected cutoffs in the Cox proportional hazards
model training sets were considered as potential optimal cutoffs. The
predictivity of these cutoffs was then assessed on the basis of HR
distribution for OS and PFS (EAGLE only). Associations of TMB with
patient demographics and baseline disease characteristics were
assessed using cutoffs of 10 mut/Mb (tTMB) and 16 mut/Mb (bTMB)
in the HAWK/CONDOR and EAGLE datasets, respectively.

Evaluation of other biomarkers
PD-L1 expression status in tumor tissue samples was determined
using the VENTANA PD-L1 (SP263) Assay (Ventana Medical Sys-
tems), with high PD-L1 expression defined as ≥25% of TCs with
membrane staining and low PD-L1 expression defined as <25% of TCs
with membrane staining. Absolute neutrophil count and absolute
lymphocyte count were assessed according to local standard to derive
NLRs.

Statistical analyses
The Kaplan–Meier method was used to calculate univariate survival
estimates. Two-sided P values were assessed using the log-rank test.
The Wilcoxon rank-sum test and Kruskal–Wallis test were used to
compare continuous variables. Analyses were performed using SAS
version 9.4 (SAS Institute) and R version 4.0.0 (R Foundation).

Data availability
Data underlying the findings described in this manuscript may be
obtained in accordance with AstraZeneca’s data sharing policy described at https://astrazenecagrouptrials.pharmacm.com/
ST/Submission/Disclosure. Anonymized datasets may be available
on request. Data for studies directly listed on Vivli can be requested
through Vivli at https://search.vivli.org/. Data for studies not list-
ed on Vivli may be requested through Vivli at https://vivli.org/
members/enquiries-about-studies-not-listed-on-the-vivli-platform/
. The request will undergo an internal review process, and if approv-
ed, data will be prepared and shared with specified accessors named
on the request form for 12 months via Vivli Secure Research Envi-
ronment. AstraZeneca Vivli member page is also available outlining
further details: https://vivli.org/ourmember/astrazeneca/
.

Results

Patient demographic and disease characteristics
tTMB was evaluable in tumor samples from 153 patients in HAWK/
CONDOR, including 78 patients who received durvalumab mono-
therapy and 48 patients who received durvalumab plus tremelimumab.
The distribution of tTMB was similar between the HAWK and
CONDOR datasets (Supplementary Fig. S1A). Patient demographics
and baseline disease characteristics of the TMB-evaluable populations
of HAWK/CONDOR were generally representative of the intent-to-
treat (ITT) populations of these studies (Supplementary Table S1). The
tTMB-high subgroup was enriched for patients who had ever smoked,
and the proportion of patients who had ever smoked was signifi-
cantly higher in the tTMB-high subgroup versus the tTMB-low subgroup
(83.3% vs. 65.2%; P = 0.017; Supplementary Table S2). No significant
difference in HPV status between the tTMB subgroups was observed.

In EAGLE, bTMB was evaluable in 247 patients, evenly distrib-
uted among the three treatment arms. The bTMB distributions were
similar among the three treatment arms of the EAGLE dataset
(Supplementary Fig. S1B). The patient demographics and disease
characteristics of the bTMB-evaluable population were generally
representative of the ITT population, except for a higher proportion
of Asian patients and a lower proportion of White patients (Sup-
plementary Table S1). The bTMB ≥16 mut/Mb subgroup included
a significantly higher proportion of patients of a race other than
White or Asian compared with the bTMB <16 mut/Mb subgroup,
though the number of patients in this race category was low (n = 10;
Supplementary Table S3).

Figure 1.
Forest plot of OS in the tTMB-high versus tTMB-low subgroups by tTMB cutoff
with durvalumab monotherapy (A) or with durvalumab plus tremelimumab (B)
in HAWK/CONDOR. HRs were calculated as tTMB-high versus -low for each
treatment group. HR, hazard ratio; OS, overall survival; TMB, tissue tumor
mutational burden.
Association of tTMB and OS in HAWK/CONDOR

In the HAWK/CONDOR dataset, OS was compared between subgroups of patients with high- versus low-tTMB in the durvalumab monotherapy and durvalumab plus tremelimumab treatment arms. For both treatment arms, the HRs of the tTMB-high versus tTMB-low subgroups generally increased with progressively higher tTMB cutoffs (Fig. 1). For durvalumab monotherapy, the 10-mut/Mb cutoff showed the best discrimination in OS between the tTMB subgroups, with high-TMB associated with prolonged OS versus low-TMB [HR, 0.72 (95% confidence interval, CI, 0.45–1.15); Fig. 1A], although differences were not significant at any of the cutoffs evaluated. For durvalumab plus tremelimumab, significant differences in OS, favoring the high-tTMB subgroup, were observed at the 10 mut/Mb [HR, 0.52 (95% CI, 0.28–0.98)] and 12 mut/Mb [HR, 0.46 (95% CI, 0.24–0.86)] cutoffs (Fig. 1B). Using the 10 mut/Mb cutoff, median OS (95% CI) in patients with high- versus low-tTMB was 9.9 (6.0–14.8) months versus 4.4 (2.9–6.1) months, respectively, with durvalumab plus tremelimumab (Fig. 2).

Association of bTMB with survival benefit in EAGLE

In the EAGLE dataset, OS and PFS were compared between patients who received durvalumab monotherapy or durvalumab plus tremelimumab versus SoC in the bTMB-high and bTMB-low subgroups. Across the evaluated cutoffs, patients in the bTMB-high subgroups had prolonged OS with durvalumab or durvalumab plus tremelimumab compared with SoC, and this OS benefit generally improved with progressively higher bTMB cutoffs (Fig. 3). In the bTMB ≥16 mut/Mb subgroup, OS and PFS were statistically significantly longer for durvalumab versus SoC (OS HR, 0.39; PFS HR, 0.48) and for durvalumab plus tremelimumab versus SoC (OS HR, 0.38; PFS HR, 0.45). The 16 mut/Mb cutoff was the only cutoff at which there was a statistically significant benefit for OS and PFS in the investigational arms compared with SoC.

The OS HRs favored the durvalumab and durvalumab plus tremelimumab arms over the SoC arm in biomarker-evaluable population (0.70 and 0.75, respectively; Fig. 4A) relative to the ITT population (0.88 and 1.04, respectively). Nevertheless, the OS benefits of durvalumab and durvalumab plus tremelimumab versus SoC were...
Figure 3.
Forest plot of OS in the bTMB-high and bTMB-low subgroups by bTMB cutoff for durvalumab monotherapy versus SoC (A) and for durvalumab plus tremelimumab versus SoC (B) and PFS in the bTMB-high and bTMB-low subgroups by bTMB cutoff for durvalumab versus SoC (C) and for durvalumab plus tremelimumab versus SoC (D) in EAGLE. HRs were calculated as durvalumab with/without tremelimumab versus chemotherapy. bTMB, blood plasma tumor mutational burden; D, durvalumab; HR, hazard ratio; OS, overall survival; PFS, progression-free survival; SoC, standard of care; tTMB, tissue tumor mutational burden.
Figure 4.
Kaplan–Meier plot of OS in the durvalumab monotherapy, durvalumab plus tremelimumab, and SoC treatment arms in the bTMB-evaluable population (A), bTMB-high subgroup (B), and bTMB-low subgroup (C). HRs were calculated as durvalumab with/without tremelimumab versus chemotherapy. bTMB, blood plasma tumor mutational burden; CI, confidence interval; HR, hazard ratio; OS, overall survival; SoC, standard of care.
substantially improved in the bTMB-high subgroup (HRs, 0.39 and 0.38, respectively; Fig. 4B). In this subgroup, significantly longer OS was observed for durvalumab and durvalumab plus tremelimumab versus SoC (median OS, 8.1 and 7.6 vs. 4.0 months, respectively), and shorter survival was observed for the SoC arm than in the biomarker-evaluable population (4.0 vs. 7.0 months). OS was not prolonged with durvalumab or durvalumab plus tremelimumab versus SoC in the TMB-low group (Fig. 4C).

**Association of bTMB and PD-L1 together with survival benefit in EAGLE**

OS for durvalumab with or without tremelimumab versus SoC was assessed in subgroups of patients in the EAGLE study categorized by bTMB and PD-L1 together (Supplementary Table S4). The small subgroup of patients with both high tumor PD-L1 expression and high TMB (n = 17) had the most OS benefit with durvalumab versus SoC [HR, 0.25 (95% CI, 0.06–1.03)] and durvalumab plus tremelimumab versus SoC [HR, 0.21 (95% CI, 0.04–1.16)].

**Association of NLR with survival benefit in EAGLE**

Baseline NLR results were available for the entire ITT population of EAGLE. A cutoff of 7 was used, based on unpublished results from a previous analysis of HAWK/CONDOR. Within the pooled ITT population, median OS was longer in patients with NLR ≤ 7 and shorter in patients with NLR > 7, irrespective of treatment [HR, 0.57 (95% CI, 0.48–0.69)]. In this analysis, there was a statistically significant survival benefit in the NLR ≤ 7 subgroup treated with durvalumab versus SoC [HR, 0.75 (95% CI, 0.57–0.97)], which was not seen in patients with NLR > 7 [HR, 1.07 (95% CI, 0.76–1.51); Supplementary Fig. S2]. No correlation was observed between NLR and bTMB (Spearman rho = 0.08).

**Discussion**

Findings from these analyses support the clinical utility of TMB in HNSCC. High tTMB was associated with longer OS versus low tTMB in patients who received either durvalumab monotherapy or durvalumab plus tremelimumab in HAWK/CONDOR. While no statistical difference was seen, this trend appeared to be greater with durvalumab plus tremelimumab, with numerical improvements in median OS observed between the high- and low-tTMB subgroups when comparing durvalumab plus tremelimumab with durvalumab monotherapy. In EAGLE, durvalumab monotherapy and durvalumab plus tremelimumab demonstrated prolonged OS versus SoC in patients with high bTMB, but not in those with low bTMB. TMB was not associated with prolonged OS in the SoC group, consistent with the proposed mechanism that TMB increases neoantigen load, thus potentiating T-cell responses to ICIs (27). The higher survival for patients with high bTMB treated with ICI therapy and relatively poor survival in the SoC arm support the predictive value of bTMB for ICI treatment rather than prognosis.

Our findings are consistent with published studies that have shown associations between high TMB and improved outcomes with ICI treatment in HNSCC (13–16). A limitation of published studies and this analysis of HAWK/CONDOR is the lack of a comparator group, thus making it impossible to rule out that TMB is a prognostic indicator. To our knowledge, this analysis of EAGLE provides the first evidence that TMB was predictive of survival with ICI treatment versus SoC.

The predictive value of bTMB for ICI treatment has also been shown in NSCLC. A study using the same hybridization-capture methodology as the FoundationOne CDx assay found that bTMB ≥ 16 mut/Mb selected for patients with NSCLC who derived a significant improvement in PFS with atezolizumab (anti-PD-L1) versus docetaxel (28). Another study using the NCC-GP150 panel, designed using WES data from The Cancer Genome Atlas, identified 6 mut/Mb as the optimal cutoff to discriminate PFS with ICIs in NSCLC (29). An analysis of the MYSTIC study using the Guardant Health OMNI platform showed prolonged OS for durvalumab plus tremelimumab versus SoC in patients with bTMB ≥ 20 mut/Mb, but not <20 mut/Mb, with a trend toward longer OS at ≥10 mut/Mb (30). Thus, clinically meaningful cutoffs for bTMB appear to vary by tumor type and methodology.

Our findings suggest that TMB may predict survival with ICIs, whether measured in tissue or blood. Measuring TMB in blood overcomes technical challenges with tissue samples and offers several advantages, including a less invasive sampling technique. Blood samples are more easily taken proximal to treatment and may better reflect current disease status compared with archived tissue. Results are less affected by intratumor heterogeneity and may represent multiple tumors simultaneously. However, tumors must be shedding a detectable level of ctDNA to analyze bTMB, and the current sensitivity of most platforms is likely to limit its use to patients with advanced or metastatic disease.

High tTMB was significantly associated with tobacco smoking in the HAWK/CONDOR dataset. This finding is consistent with a previous study showing that smoking caused specific mutational signatures in tumors, associated with increased overall mutation count (31). Infection with HPV has been shown to be an independent risk factor for HNSCC, and HPV-positive HNSCCs represent a distinct genetic subset of tumors (32). We did not find an association between tTMB or bTMB and HPV status.

Although no statistical testing was performed, the OS benefit of durvalumab or durvalumab plus tremelimumab versus SoC for patients with high bTMB appeared to be numerically higher than for those with high PD-L1 in EAGLE (5). The predictive value of bTMB also compares favorably to PD-L1 in other clinical trials of ICIs in platinum-resistant R/M HNSCC. In CheckMate 141, the OS HR for nivolumab versus SoC in the PD-L1-high subgroup was 0.55 (3). A similar HR of 0.53 was observed for pembrolizumab versus SoC in patients with a PD-L1 tumor proportion score ≥50% in KEYNOTE-040 (4). In KEYNOTE-040, the prevalence of high PD-L1 expression was 26% (4), similar to the prevalence of high tTMB in EAGLE. Consistent with findings in other tumor types (33), our analysis showed that tTMB and PD-L1 were independent. Furthermore, selecting for high TMB and PD-L1 together resulted in improved OS HRs for durvalumab and durvalumab plus tremelimumab versus SoC, compared with either biomarker alone, although this population was small and results were not significant.

Analysis of OS in NLR subgroups demonstrated that NLR was prognostic across the entire population and predictive of OS benefit for durvalumab monotherapy versus SoC. Other studies have reported predictive value for NLR for ICI treatment in HNSCC (34–36). Using a cutoff of 8.77, Foster and colleagues observed that NLR was more strongly associated with outcome than PD-L1 in patients receiving anti-PD-1 therapy. NLR measurement in the clinical setting is routine and may offer useful information for the selection of patients for ICI treatment. However, an optimal threshold is yet to be determined.

Limitations of the study included that it was retrospective and the incomplete ascertainment of samples. Archival tumor samples up to 3 years old from HAWK/CONDOR were used for the tTMB analysis and may have not been representative of tTMB at the time of treatment. The bTMB analysis was performed on plasma samples.
collected at baseline from patients in the EAGLE study and, compared with archival tumor samples for tMB analysis, may more accurately reflect the disease stage at the time of treatment. A direct comparison of tTMB and bTMB analyses in the same study population was not performed and would have enabled a direct comparison of the two methods. The number of samples included in the analyses was relatively small, particularly for tTMB. This precluded the assessment of the impact of any imbalances in baseline characteristics, such as smoking status, and may explain why a trend, but no significant difference, in OS was seen in patients that were tTMB-high and treated with durvalumab monotherapy in HAWK/CONDOR when a significant difference was observed in EAGLE. Another limitation of the tTMB analysis was that it was performed using samples from two studies with distinct patient populations. For example, HAWK was restricted to PD-L1–high patients, whereas CONDOR was restricted to PD-L1–low patients. Taking this into account, there is a risk that selection bias may have influenced outcomes. However, this limitation did not apply to the STMB analysis as it used samples from EAGLE, an unsselected, randomized study with a chemotherapy control arm.

While definitive data on the clinical utility of TMB are lacking, our findings suggest that TMB is a promising biomarker for predicting survival with ICI treatment in R/M HNSCC, particularly for the combination of immunotherapy plus chemotherapy. Cutoffs need to be optimized for methodologies used. This analysis provides evidence that 16 mut/Mb is the optimal cutoff for bTMB using the Guardant Health OMNI platform to identify patients with HNSCC who have hypermutated tumors and may benefit from ICI treatment. Prospective evaluation of TMB and validation of the high-bTMB (16 mut/Mb) cutoff in large, randomized clinical trials is warranted. Whether these findings can be translated to the first-line setting for patients with HNSCC remains to be determined.

Authors' Disclosures
S. Wildsmith reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from AstraZeneca outside the submitted work; in addition, S. Wildsmith has a patent for WO2021/228988 pending. W. Li reports other support from AstraZeneca during the conduct of the study, as well as other support from AstraZeneca outside the submitted work; in addition, W. Li has a patent for Biomarkers for Predicting OS in Recurrent Metastatic Head and Neck Squamous Cell Carcinoma pending to AstraZeneca. R. Stewart reports other support from AstraZeneca during the conduct of the study, as well as other support from Pfizer Inc outside the submitted work. N. Morsi reports other support from AstraZeneca during the conduct of the study. R. Raja reports other support from AstraZeneca outside the submitted work; in addition, R. Raja has a patent for tumor mutational burden pending. Q. Zhang reports personal fees from Merck KGaA, as well as grant support from Merck KGaA, outside the submitted work; in addition, Q. Zhang has a patent for WO2021/228988 A1 pending. P. He was an AstraZeneca employee at the time of the article preparation. A. Yovine reports other support from AstraZeneca outside the submitted work. N. Holowecy reports personal fees (employment) from AstraZeneca. J. Walker reports personal fees from AstraZeneca during the conduct of the study, as well as personal fees from AstraZeneca outside the submitted work; in addition, J. Walker is an employee and shareholder of AstraZeneca. M. de los Reyes reports other support from AstraZeneca outside the submitted work. C. Barker reports other support from AstraZeneca outside the submitted work. R. Haddad reports personal fees from Merck, Bayer, GlaxoSmithKline, Eisai, Bayer, Merck Serono, Kura Oncology, Novartis, and BMS, as well as personal fees from Pfizer, Kura Oncology, Merck, Merck Serono, and BMS outside the submitted work. L. Licitra reports grants from Adlai Nortye, AstraZeneca, BMS, Debiopharm International SA, Eisai, Eli Lilly and Company, Excelitas, Hoffmann-La Roche Ltd, Isa Therapeutics, Kura Oncology, Merck Serono, MSD, Merck Sharp & Dohme Corp, Nektar Therapeutics, Novartis, Regeneron, Roche, Sanofi, Syneos, and Sun Pharmaceutical during the conduct of the study, as well as personal fees from Adlai Nortye, AstraZeneca, Bicara Therapeutics, DRG (part of Clarivate), Gemmah US, GlaxoSmithKline, Bayer, Mirati Therapeutics, MSD, Merck Serono, Merck Healthcare KGaA, Neuron Therapeutics Inc., and Seagen International BnBh outside the submitted work. R. Ferris reports personal fees from Adagene Incorporated, Ardoo Biotech, Brooklyn Immunotherapeutics LLC, Catenon, EMD Serono, Everett Clinical Research Corp, F. Hoffmann-La Roche Ltd, Federation Bio, Inc, Genexa Biosciences, Inc, Kowa Research Institute, Inc, Mirati Therapeutics, Inc, Nanobiotics, Novartis Pharmaceutical Inc, PPD Development LP, Sanofi, and Zymeworks, Inc; grants from AstraZeneca/MedImmune, Bicara Therapeutics Inc and Tesaro; grants and other support from Bristol Myers Squibb and Merck; other support from Coherus BioSciences, Eisai Europe Limited, Gemmah, Hookeia Biotech GmbH, InstBio, Inc, LifeScience Dynamics Limited, MacroGenics Inc, MuraTax LLC, Mirror Biosciences Inc, Nambum Therapeutics AG, Oncoyce Corporation, Pfizer, Rauschenberg Medical Inc, Seagen, Inc, SIRPant Immunotherapeutics, and Vir Biotechnology Inc; and grants, personal fees, and other support from Novasenta outside the submitted work. J. Fayette reports grants and personal fees from BMS, personal fees and non-financial support from MSD, grants, personal fees, and non-financial support from AstraZeneca; and personal fees from Innate Pharma, Roche, and Merck Serono during the conduct of the study. D.P. Zandberg reports personal fees from Merck, Macrogenics, Blueprint Medicines, and Prelude Therapeutics, as well as grants from Merck, BMS, AstraZeneca, GlaxoSmithKline, BICARA, Novasenta, and Macrogenics during the conduct of the study. L.I. Siu reports personal fees from AstraZeneca, as well as grants from AstraZeneca during the conduct of the study; in addition, L.I. Siu reports personal fees from Merck, Pfizer, Roche-Gentech, GlaxoSmithKline, Voronoi, Arvins, Tessa, Navire, Relay, Daichi Sankyo, Amgen, Marengo, Medicenna, Tubulis, LTZ Therapeutics, Agios, and Treadwell Therapeutics, as well as grants from Novartis, Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, GlaxoSmithKline, Roche-Gentech, Merck, Bayer, AbbVie, Amgen, Synthogen, Intensity Therapeutics, Mirati, Shattucks Laboratory, BienTec, 23Me, and EMD Serono outside the submitted work. R. Mesia reports other support from Merck KGaA, MSD, Pierre-Fabre, Bayer, Roche, Gemlab, Nanobiotics, and Boehringer-Ingelheim outside the submitted work. No disclosures were reported by the other authors.

Authors' Contributions
S. Wildsmith: Conceptualization, data curation, formal analysis, supervision, methodology, project administration, writing–review and editing. W. Li: Conceptualization, data curation, formal analysis, supervision, methodology, writing–review and editing. S. Wu: Formal analysis, writing–review and editing. R. Stewart: Formal analysis, project administration, writing–review and editing. N. Morsi: Supervision, writing–review and editing. R. Raja: Formal analysis, supervision, writing–review and editing. Q. Zhang: Formal analysis, project administration, writing–review and editing. M. de los Reyes: Data curation, project administration, writing–review and editing. J. Walker: Conceptualization, formal analysis, methodology, writing–review and editing. S. Wu: Formal analysis, writing–review and editing. M. Wrona: Data curation, project administration, writing–review and editing. S. Wildsmith: Data curation, project administration, writing–review and editing. J. Ye: Formal analysis, writing–review and editing. P. He: Formal analysis, writing–review and editing. J. Whiteley: Data curation, project administration, writing–review and editing. M. de los Reyes: Data curation, project administration, writing–review and editing. C. Barker: Data curation, project administration, writing–review and editing. J. Whiteley: Data curation, project administration, writing–review and editing. R. Haddad: Data curation, formal analysis, writing–review and editing. L. Licitra: Data curation, formal analysis, writing–review and editing. R. Ferris: Data curation, formal analysis, writing–review and editing. J. Fayette: Data curation, formal analysis, writing–review and editing. D. P. Zandberg: Data curation, formal analysis, writing–review and editing. L. Licitra: Data curation, formal analysis, writing–review and editing. L. Licitra: Data curation, formal analysis, writing–review and editing. L. Licitra: Data curation, formal analysis, writing–review and editing. L. Licitra: Data curation, formal analysis, writing–review and editing. R. Mesia: Data curation, formal analysis, writing–review and editing.

Acknowledgments
The authors thank the patients who volunteered to participate in the HAWK, CONDOR, and EAGLE studies and their families, as well as all of the investigators and study site personnel. We thank Ward A. Pedersen and Anne-Marie Manwaring of Parexel for medical writing and editorial assistance, and Sara Gibson of CMC Connect, a division of IPG Health Medical Communications for editorial assistance, which were funded by AstraZeneca. This study was funded by AstraZeneca.

The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.

Note
Supplementary data for this article are available at Clinical Cancer Research Online (http://clincancerres.aacrjournals.org/).

Received October 13, 2022; revised December 19, 2022; accepted February 15, 2023; published first February 20, 2023.
References


